BERGENBIO Stock Is 12% Up So Far On Tuesday

(VIANEWS) – Shares of BERGENBIO (Oslo Børs Benchmark Index_GI: BGBIO.OL) jumped by a staggering 12.41% to kr0.09 at 11:24 EST on Tuesday, after two consecutive sessions in a row of gains. Oslo Børs Benchmark Index_GI is sliding 0.21% to kr1,199.10, after two successive sessions in a row of gains. This seems, up to now, a somewhat negative trend exchanging session today.

About BERGENBIO

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma. In addition, the company is developing tilvestamab, an anti-AXL function-blocking monoclonal antibody that is in Phase 1b clinical trial for the treatment of ovarian cancer; and mipasetamab uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. It has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.

Earnings Per Share

As for profitability, BERGENBIO has a trailing twelve months EPS of kr-2.61.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BERGENBIO’s stock is considered to be oversold (<=20).

More news about BERGENBIO (BGBIO.OL).

Leave a Reply

Your email address will not be published. Required fields are marked *